Study aid only. Verify against current guidelines before clinical use.

All 1,600+ trial summaries

Trials · Breast Cancer · HR+ advanced

MONALEESA-2

Hortobagyi GN et al, Ann Oncol, 2022; PMID: 35085735

Summarized and reviewed by Veli Bakalov, MD · Updated

Medical OncologyBreast CancerHR+ advanced2022

At a glance

Ribociclib plus letrozole improved both PFS and OS, solidifying CDK4/6 inhibitor plus AI as first-line standard in postmenopausal HR+ HER2- mBC; QTc monitoring is required.

Population
Postmenopausal women with HR+ HER2- recurrent or metastatic breast cancer, no prior systemic therapy for advanced disease (N=668)
Design
Phase III, double-blind, placebo-controlled RCT
Arms
Ribociclib + letrozole vs placebo + letrozole
Primary endpoint
Progression-free survival (PFS)
Key result
PFS 25.3 vs 16.0 mo, HR 0.568, 95% CI 0.457-0.704, P<.001; final OS 63.9 vs 51.4 mo, HR 0.76, 95% CI 0.63-0.93, P=.004
Background
Phase III, double-blind, placebo-controlled RCT. 668 postmenopausal women with HR+ HER2- locally recurrent or metastatic breast cancer with no prior systemic therapy for advanced disease. Visceral crisis excluded.
Interventions and follow up
Arm A: Ribociclib 600mg days 1–21 of 28-day cycle + letrozole 2.5mg daily
Arm B: Placebo + letrozole 2.5mg daily
Primary endpoint: Progression-free survival (PFS)
mFollow up: 79.0 months (OS analysis)
Results
PFS: 25.3 vs 16.0mo, HR 0.568, 95% CI 0.457–0.704, P<.001
OS (final): 63.9 vs 51.4mo, HR 0.76, 95% CI 0.63–0.93, P=.004
Adverse events
Hematologic (grade ≥3): Neutropenia 59.3% vs 0.9%; febrile neutropenia 1.9%
Cardiac: QTc prolongation grade ≥3 3.3%
Hepatic: Hepatotoxicity grade ≥3 10.0%
Dose modification: Ribociclib dose reduction 44.9%; discontinuation 7.5%
Conclusions
Ribociclib + letrozole significantly improved both PFS and OS vs letrozole alone in postmenopausal HR+ HER2- mBC, with an OS benefit of ~12.5 months. MONALEESA-2 provided one of the first OS benefits demonstrated for CDK4/6 inhibition in first-line HR+ mBC.
Key Limitations
QTc prolongation requires baseline ECG and ongoing monitoring, limiting use in patients with cardiac risk factors or concurrent QT-prolonging agents. OS analysis is from a secondary endpoint — PFS was the primary. Letrozole-only backbone may underestimate benefit of ribociclib added to fulvestrant in 2nd-line (addressed in MONALEESA-3). All-postmenopausal population limits generalizability to premenopausal patients (addressed in MONALEESA-7).
Clinical Context
MONALEESA-2 OS data helped solidify CDK4/6 inhibitor + AI as the standard of care in first-line postmenopausal HR+ HER2- mBC. Ribociclib's OS benefit across MONALEESA-2/3/7 is considered class-leading evidence among CDK4/6 inhibitors. ESMO-MCBS score: 5. Requires QTc monitoring; preferred over palbociclib in patients where OS data is a priority consideration.
References
Hortobagyi GN et al, Ann Oncol 2022 (final OS) | Hortobagyi GN et al, NEJM 2016 (initial PFS)
Open in the interactive trials browser View source ↗
HemeOncBuddy Clinical Trials Pivotal trial summaries in hematology and oncology Browse 1,600+ summaries by disease, filter by area or search by drug. Open all trial summaries